Xeris Biopharma Holdings Inc (XERS) has a current Price-to-Book (P/B) ratio of -1413.19. Compared to its 3-year average P/B ratio of -151.89, the current P/B ratio is approximately 830.41% higher. Relative to its 5-year average P/B ratio of -103.54, the current P/B ratio is about 1264.90% higher. Xeris Biopharma Holdings Inc (XERS) has a Forward Free Cash Flow (FCF) yield of approximately 0.82%. Compared to its 3-year average FCF yield of -13.56%, the current FCF yield is approximately -106.03% lower. Relative to its 5-year average FCF yield of -24.42%, the current FCF yield is about -103.35% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for XERS competitors is 9.32, providing a benchmark for relative valuation. Xeris Biopharma Holdings Inc Corp (XERS.O) exhibits a P/S ratio of 3.41, which is -63.38% above the industry average. Given its robust revenue growth of 37.06%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of XERS increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of XERS in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is XERS currently overvalued or undervalued?

What is Xeris Biopharma Holdings Inc (XERS) fair value?

XERS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Xeris Biopharma Holdings Inc (XERS) is between 5.85 to 8.04 according to relative valuation method.

How does XERS's valuation metrics compare to the industry average?

The average P/S ratio for XERS's competitors is 9.32, providing a benchmark for relative valuation. Xeris Biopharma Holdings Inc Corp (XERS) exhibits a P/S ratio of 3.41, which is -63.38% above the industry average. Given its robust revenue growth of 37.06%, this premium appears sustainable.

What is the current P/B ratio for Xeris Biopharma Holdings Inc (XERS) as of Mar 02 2026?

As of Mar 02 2026, Xeris Biopharma Holdings Inc (XERS) has a P/B ratio of -1413.19. This indicates that the market values XERS at -1413.19 times its book value.

What is the current FCF Yield for Xeris Biopharma Holdings Inc (XERS) as of Mar 02 2026?

As of Mar 02 2026, Xeris Biopharma Holdings Inc (XERS) has a FCF Yield of 0.82%. This means that for every dollar of Xeris Biopharma Holdings Inc's market capitalization, the company generates 0.82 cents in free cash flow.

What is the current Forward P/E ratio for Xeris Biopharma Holdings Inc (XERS) as of Mar 02 2026?

As of Mar 02 2026, Xeris Biopharma Holdings Inc (XERS) has a Forward P/E ratio of 60.39. This means the market is willing to pay $60.39 for every dollar of Xeris Biopharma Holdings Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Xeris Biopharma Holdings Inc (XERS) as of Mar 02 2026?

As of Mar 02 2026, Xeris Biopharma Holdings Inc (XERS) has a Forward P/S ratio of 3.41. This means the market is valuing XERS at $3.41 for every dollar of expected revenue over the next 12 months.

XERS Valuation